TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer.
暂无分享,去创建一个
S. Lam | W. Lam | A. Karsan | A. Gazdar | M. Tsao | R. Chari | W. Lockwood | M. Fuller | D. Starczynowski | J. Węgrzyn | Sophie Deléhouzée | Megan E Fuller
[1] C. Paweletz,et al. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors , 2010, BMC Medical Genomics.
[2] A. Baldwin,et al. Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. , 2010, Cancer research.
[3] Yeul-Hong Kim,et al. Genomic alterations of chromosome region 11p as predictive marker by array comparative genomic hybridization in lung adenocarcinoma patients. , 2010, Cancer genetics and cytogenetics.
[4] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[5] Ryan D. Morin,et al. Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype , 2010, Nature Medicine.
[6] D. Feldser,et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma , 2009, Nature.
[7] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[8] Elizabeth E. Molnar,et al. TRAF6 Autoubiquitination-Independent Activation of the NFκB and MAPK Pathways in Response to IL-1 and RANKL , 2008, PloS one.
[9] Bradley P. Coe,et al. Integrative genomic and gene expression analysis of chromosome 7 identified novel oncogene loci in non-small cell lung cancer. , 2008, Genome.
[10] A. Telenius,et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. , 2008, Blood.
[11] Calum MacAulay,et al. SIGMA2: A system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes , 2008, BMC Bioinformatics.
[12] S. Lippman,et al. Lung cancer. , 2008, The New England journal of medicine.
[13] Dafydd G. Thomas,et al. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. , 2008, Cancer research.
[14] Igor Jurisica,et al. Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.
[15] B. Coe,et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers , 2008, Oncogene.
[16] J. Flores,et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. , 2008, Cancer cell.
[17] Lin Ji,et al. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras , 2008, Molecular Cancer Therapeutics.
[18] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[19] Derek Y. Chiang,et al. Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.
[20] A. Karsan,et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. , 2007, The Journal of experimental medicine.
[21] Jude Kendall,et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer , 2007, Proceedings of the National Academy of Sciences.
[22] L. Staudt,et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.
[23] L. Bruhn,et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.
[24] Levi A Garraway,et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. , 2007, Cancer research.
[25] K. Robertson,et al. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer , 2007, Oncogene.
[26] Carolyn J. Brown,et al. A comprehensive analysis of common copy-number variations in the human genome. , 2007, American journal of human genetics.
[27] Bharat B. Aggarwal,et al. Nuclear factor‐κB (nf‐κB) is frequently expressed in lung cancer and preneoplastic lesions , 2006 .
[28] J. Minna,et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. , 2006, Cancer cell.
[29] A. Gazdar,et al. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.
[30] Calum MacAulay,et al. Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small‐cell lung cancer cell lines , 2006, Genes, chromosomes & cancer.
[31] A. Hoffmann,et al. Immortalized fibroblasts from NF-κB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor α after transformation by v-Ras , 2005, Oncogene.
[32] M. Meyerson,et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. , 2005, Cancer research.
[33] R. Siebert,et al. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[34] Elena Marchiori,et al. Breakpoint identification and smoothing of array comparative genomic hybridization data , 2004, Bioinform..
[35] Bradley P. Coe,et al. A tiling resolution DNA microarray with complete coverage of the human genome , 2004, Nature Genetics.
[36] A. Rao. Faculty Opinions recommendation of CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. , 2003 .
[37] A. Ashworth,et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members , 2003, Nature.
[38] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[39] L. Hood,et al. Activated Notch4 Inhibits Angiogenesis: Role of β1-Integrin Activation , 2002, Molecular and Cellular Biology.
[40] Young Chul Park,et al. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. , 2002, Journal of cell science.
[41] R. Gascoyne,et al. TNFR-Associated Factor Family Protein Expression in Normal Tissues and Lymphoid Malignancies , 2000, The Journal of Immunology.
[42] A. Ashworth,et al. Identification of the familial cylindromatosis tumour-suppressor gene , 2000, Nature Genetics.
[43] R. Weinberg,et al. Analysis of viral and somatic activations of the cHa-ras gene , 1985, Journal of virology.